Tomasz M. Beer, MD

home / authors / tomasz-m-beer-md

Articles

Building on Last Year’s Advances

Tomasz M. Beer, MD

July 15th 2015

The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

Julie N. Graff, MD;Tomasz M. Beer, MD

June 15th 2015

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Targeted Therapy in Prostate Cancer: Is There Hope Beyond the Androgen Receptor?

Joshi J. Alumkal, MD;Julie N. Graff, MD;Tomasz M. Beer, MD

July 15th 2013

We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time-for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Andrew J. Armstrong, MD, MSc;Tomasz M. Beer, MD

April 27th 2012

Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.